Trial · NCT02584634
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
NCT02584634, Phase 1, Phase 2, Terminated, Pfizer; results first posted 2022-02-09
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101). Trials, record NCT02584634. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02584634
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
- NCT number
- NCT02584634
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 43 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Avelumab, PF-06463922, Crizotinib
- First posted
- 2015-10-22
- Last updated
- 2023-07-07
- Other registries' IDs
- eudract:2015-001879-43
- Results first posted
- 2022-02-09
- Limitations and caveats
Enrollment in the study was terminated early based on the changing landscape in treatment options for treatment naïve ALK positive NSCLC. This decision was not due to any safety concerns or regulatory interactions. All participants on active treatment at the time of the early enrollment termination could continue treatment and follow up per the protocol.
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | First 2 cycles (1 cycle = 14 days) | Any of the following adverse events (AEs) occurring during the primary DLT observation period that are attributable to one, the other, or both study drugs were classified as DLTs: Grade 4 (life-threatening) neutropenia if \>7 days in duration; febrile neutropenia; Grade \>=3 (severe or life threatening) neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia \>7 days; Grade 4 anemia; any Grade \>=3 toxicity, except for any of the following: transient (\<=6 hours) Grade 3 (severe) flu like symptoms or fever; transient (\<=24 hours) Grade 3 fatigue, local reactions, or headache that resolved to Grade \<=1 (no AE or mild AE); Grade 3 nausea and/or vomiting, diarrhea or skin toxicity that resolved to Grade \<=1 within 7 days; any Grade \>=3 amylase or lipase abnormality; tumor flare phenomenon; single laboratory values out of normal range that were not related to treatment, did not have any clinical correlate, and resolve to Grade \<=1 within 7 days. |
| Primary | Percentage of Participants With Objective Response (OR): Phase 2 | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | OR is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 from start date (the date of first dose of study treatment) until disease progression or death due to any cause. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. |
| Primary | Percentage of Participants With CR for Group B: Phase 2 | Baseline up to 60 months | Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis). |
| Secondary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Baseline up to 30 days after last dose of study treatment or the day before start day of new anti-cancer therapy (maximum of 5 years) | TEAEs are those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period. Treatment-related AEs was any untoward medical occurrence attributed to study drug in a participant who received study drug. Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03: Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment; Grade 4 (Life-threatening) events caused participant to be in imminent danger of death; Grade 5 (Death) events=death related to an AE. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. |
| Secondary | Number of Participants With Baseline Laboratory Abnormalities Grade <=2 and Post-Baseline Laboratory Abnormalities of Grades 3 or 4 Per NCI CTCAE v4.03 | Screening up to end of treatment/withdrawal (maximum of 5 years) | The laboratory results were graded according to the NCI CTCAE v4.03 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Shift tables were provided to examine the distribution of laboratory toxicities. The following parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: anemia, lymphocyte count decreased, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, Creatine phosphokinase (CPK) increased, Gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hypermagnesemia, hypertriglyceridemia, hypoalbuminemia, hyponatremia, lipase increased, serum amylase increased. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. |
| Secondary | Number of Participants With Vital Signs Meeting Pre-defined Criteria | Screening up to end of treatment/withdrawal (maximum of 5 years) | Pre-defined criteria in vital signs: pulse rate \<50 beats per minute, pulse rate \>120 bpm, sitting diastolic blood pressure (DBP) increase and decrease in change from baseline of \>= 20 millimeter of mercury (mmHg), sitting systolic blood pressure(SBP) \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. |
| Secondary | Disease Control Rate (DCR) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | DC is defined as objective response (CR or PR) or stable disease (SD) per RECIST v.1.1 from the date of first dose of study treatment until disease progression or death due to any cause. The DCR is the proportion of patients with DC. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. |
| Secondary | Duration of Response (DR) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | DR: time from first documented occurrence of response (PR or CR) until date of first documented PD or death due to underlying cancer. Per RECIST 1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions; any pathological lymph nodes assigned as target lesions/non-target lesions have a reduction in short axis to \<10 mm. PR: at least a \>=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters. PD: at least a \>=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of new lesions. Participants with no PD and were still alive by 02 Feb 2020, were censored at last adequate tumor assessment. Kaplan-Meier method was used for DR analysis. |
| Secondary | Time to Tumor Response (TTR) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | TTR is defined, for participants with an objective response (CR or PR), as the time from the start date (the date of first dose of treatment) to the first documentation of objective response (CR or PR) which is subsequently confirmed. Per RECIST v1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions/ non-target lesions must have a reduction in short axis to \<10 mm. PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters. |
| Secondary | Progression-free Survival (PFS) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | PFS is defined as the time from start date (the date of first dose of treatment) to the date of the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST v1.1: PD: a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes32
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | First 2 cycles (1 cycle = 14 days) | The analysis population included all participants enrolled in Phase 1b who were in the safety analysis set (all participants who received at least one dose of study drug), and either experienced DLT during the first 2 cycles (1 cycle = 14 days), or completed the observation period for the first 2 cycles of treatment. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Percentage of Participants With Objective Response (OR): Phase 2 | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With CR for Group B: Phase 2 | Baseline up to 60 months | The analysis population included all participants who received at least one dose of study drug in Group B. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received. Results for Group A are not reported for this outcome measure according to the protocol. | Percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Baseline up to 30 days after last dose of study treatment or the day before start day of new anti-cancer therapy (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one study treatment, the participant were classified according to the first treatment received. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Baseline Laboratory Abnormalities Grade <=2 and Post-Baseline Laboratory Abnormalities of Grades 3 or 4 Per NCI CTCAE v4.03 | Screening up to end of treatment/withdrawal (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug and who could be evaluated for CTCAE criteria for each parameter in each treatment group. Participants were classified according to the study treatment actually received. If a participant received more than one study treatment, the participant was classified according to the first treatment received. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Vital Signs Meeting Pre-defined Criteria | Screening up to end of treatment/withdrawal (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one study treatment, the participant was classified according to the first treatment received. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Disease Control Rate (DCR) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received. | Percentage of participants | NUMBER |
| SECONDARY | Duration of Response (DR) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug and who had confirmed complete response or partial response. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received. | Month | MEDIAN |
| SECONDARY | Time to Tumor Response (TTR) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug and who had confirmed complete response or partial response. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received. | Months | MEDIAN |
| SECONDARY | Progression-free Survival (PFS) | Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years) | The analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received. | Months | MEDIAN |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 outcomesResults by group172
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | Group A: Avelumab + Crizotinib | 5 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | Group B: Avelumab + Lorlatinib | 2 | Participants | ||
| Percentage of Participants With Objective Response (OR): Phase 2 | Group A: Avelumab + Crizotinib | 25.0 | 95% Confidence Interval 5.5 to 57.2 | Percentage of participants | |
| Percentage of Participants With Objective Response (OR): Phase 2 | Group B: Avelumab + Lorlatinib | 51.6 | 95% Confidence Interval 33.1 to 69.8 | Percentage of participants | |
| Percentage of Participants With CR for Group B: Phase 2 | Group B: Avelumab + Lorlatinib | 3.2 | Percentage of participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with TEAEs | 12 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with TEAEs | 30 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with Grade >= 3 TEAEs | 7 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with Grade >= 3 TEAEs | 23 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with treatment-related TEAEs | 12 | Participants |
1 to 10 of 172Source ClinicalTrials.gov
See all 172 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A: Avelumab + Crizotinib | 12 | |
| Overall Study | STARTED | Group B: Avelumab + Lorlatinib | 31 | |
| Overall Study | COMPLETED | Group A: Avelumab + Crizotinib | 0 | |
| Overall Study | COMPLETED | Group B: Avelumab + Lorlatinib | 0 | |
| Overall Study | NOT COMPLETED | Group A: Avelumab + Crizotinib | 12 | |
| Overall Study | NOT COMPLETED | Group B: Avelumab + Lorlatinib | 31 |
Source ClinicalTrials.gov
Adverse events304
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Group A: Avelumab + Crizotinib | 3 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | Group B: Avelumab + Lorlatinib | 6 | 31 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Group B: Avelumab + Lorlatinib | 0 | 31 | |
| other | Atrioventricular block first degree | Cardiac disorders | Group A: Avelumab + Crizotinib | 0 | 12 | |
| other | Atrioventricular block first degree | Cardiac disorders | Group B: Avelumab + Lorlatinib | 2 | 31 | |
| other | Pericardial effusion | Cardiac disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Pericardial effusion | Cardiac disorders | Group B: Avelumab + Lorlatinib | 1 | 31 | |
| other | Tinnitus | Ear and labyrinth disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Tinnitus | Ear and labyrinth disorders | Group B: Avelumab + Lorlatinib | 1 | 31 |
1 to 10 of 304Source ClinicalTrials.gov
See all 304 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A: Avelumab + Crizotinib | 10 | 12 |
| Total, all-cause mortality | Group B: Avelumab + Lorlatinib | 15 | 31 |
| Total, other adverse events | Group A: Avelumab + Crizotinib | 12 | 12 |
| Total, other adverse events | Group B: Avelumab + Lorlatinib | 28 | 31 |
| Total, serious adverse events | Group A: Avelumab + Crizotinib | 5 | 12 |
| Total, serious adverse events | Group B: Avelumab + Lorlatinib | 21 | 31 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39034968 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Group A: Avelumab + Crizotinib vs Group B: Avelumab + Lorlatinib: Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | Trial comparisons |
| Group A: Avelumab + Crizotinib vs Group B: Avelumab + Lorlatinib: deaths from any cause | Trial comparisons |
| Group A: Avelumab + Crizotinib vs Group B: Avelumab + Lorlatinib: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02584634
GET https://conductscience.org/api/trials/v1/NCT02584634/registered?page=2